ASND · Ascendis Pharma A/S · Documents
$234.33
+4.38 (+1.90%)
At close · Oct 20
Return incl. dividend (before tax)
Market Cap
$15.39B
Shares
65.80M
Volume · Oct 20
394.83K
Avg daily vol (3M)
686.74K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 6-K | Ascendis Pharma A/S announced the CHMP adopted a positive opinion recommending EU marketing authorization for once-weekly TransCon CNP (navepegritide) for achondroplasia in children two years and older. The EC decision is expected in Q4 2026. | 2026-10-16 | — | |
| 6-K | Ascendis Pharma A/S’s board granted 35,890 employee warrants on October 13, 2026 at US $223.21 per share; each permits subscription for one ordinary share. Warrants for 1,459,173 additional shares remain available. | 2026-10-14 | — | |
| 6-K | — | 2026-09-29 | — | |
| Investor Event Transcript | — | 2026-09-15 | 2026-09-30 | |
| 6-K | — | 2026-09-15 | 2026-09-14 | |
| 6-K | — | 2026-09-15 | 2026-09-14 | |
| 6-K | — | 2026-09-09 | — | |
| 6-K | — | 2026-09-09 | — | |
| 6-K | — | 2026-08-31 | — | |
| 6-K | — | 2026-08-13 | 2026-06-30 | |
| 6-K | — | 2026-08-13 | — | |
| 6-K | — | 2026-08-12 | — | |
| 6-K | — | 2026-08-06 | — | |
| 6-K | — | 2026-07-15 | — | |
| 6-K | — | 2026-06-30 | — | |
| 6-K | — | 2026-06-29 | — | |
| 6-K | — | 2026-06-17 | — | |
| 6-K | — | 2026-06-15 | — | |
| 6-K | — | 2026-06-12 | — | |
| 6-K | — | 2026-06-10 | — | |
| 6-K | — | 2026-05-13 | — | |
| 6-K | — | 2026-05-07 | 2026-03-31 | |
| 6-K | — | 2026-05-07 | — | |
| 6-K | — | 2026-04-21 | — | |
| 6-K | — | 2026-04-21 | — | |
| 6-K | — | 2026-04-20 | — | |
| 6-K | — | 2026-04-16 | 2026-04-15 | |
| 6-K | — | 2026-04-08 | — | |
| 6-K | — | 2026-04-08 | — | |
| 6-K | — | 2026-04-07 | 2026-04-06 | |
| 6-K | — | 2026-03-30 | — | |
| 6-K | — | 2026-03-24 | — | |
| 6-K | — | 2026-03-17 | — | |
| 6-K | — | 2026-03-16 | — | |
| 6-K | — | 2026-03-11 | — | |
| 6-K | — | 2026-03-02 | 2026-02-28 | |
| 6-K | — | 2026-02-23 | — | |
| 6-K | — | 2026-02-11 | 2026-02-10 | |
| 20-F | — | 2026-02-11 | 2025-12-31 | |
| 6-K | — | 2026-02-11 | — | |
| 6-K | — | 2026-01-14 | — | |
| 6-K | — | 2026-01-12 | — | |
| 6-K | — | 2026-01-09 | 2026-01-08 | |
| 6-K | — | 2025-12-30 | — | |
| 6-K | — | 2025-12-10 | — | |
| 6-K | — | 2025-11-26 | 2025-11-25 | |
| 6-K | — | 2025-11-12 | — | |
| 6-K | — | 2025-11-12 | 2025-09-30 | |
| 6-K | — | 2025-11-12 | — | |
| 6-K | — | 2025-10-22 | — |
Showing 1–50 of 299 filings
Key facts
CIK
1612042
CUSIP
K08588103
13F (30d)
25 filings
25 filers
Visit website
Investor relations